PI3K Inhibitors of Novel Hydrazide Analogues Linked 2-Pyridinyl Quinazolone Scaffold as Anticancer Agents
Table 1
Cytotoxic activity of the newly synthesized compounds against human carcinoma cell lines at 100 μM.
Compounda
Growth inhibition (mean ± SEM) (%)
HePG-2
MCF-7
HCT-116
3a
35.2 ± 2.52
52.5 ± 2.40
19.3 ± 2.23
3b
33.5 ± 1.65
12.6 ± 1.15
0
6
5.3 ± 0.81
37.8 ± 1.13
0
7
4.3 ± 1.86
12.5 ± 2.45
14.4 ± 2.90
8
12.2 ± 2.27
9.6 ± 1.70
11.8 ± 3.58
9
100 ± 0.00
9.3 ± 1.45
20.4 ± 4.35
12
90.1 ± 6.60
39.1 ± 1.95
0
13a
41 ± 3.20
8.4 ± 1.47
19.2 ± 2.00
13b
21 ± 2.08
10.2 ± 2.35
0
14b
10 ± 2.25
10.2 ± 1.56
11.2 ± 2.51
15a
20.1 ± 2.05
6.2±1.10
17.1 ± 1.95
15b
2.1 ± 2.15
2.3 ± 1.66
9.3 ± 0.90
16a
98.2 ± 1.11
4.2 ± 1.00
37.3 ± 1.96
17b
25.6 ± 4.51
67.3 ± 2.43
25.1 ± 4.99
17d
22.1 ± 2.85
0
0
Negative controlb
0
0
0
Doxorubicina
100 ± 0.00
100 ± 0.00
100 ± 0.00
aConcentration of test compounds and positive control (doxorubicin) was 100 μM; buntreated cells in DMSO and its final concentration in the cells was less than 0.2%.
